Medicenna Therapeutics Corp - MDNA STOCK NEWS

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) received a 180-day extension from Nasdaq to comply with the minimum bid price requirement of $1.00 per share, extending the deadline to October 23, 2023. The company was initially notified of non-compliance on October 25, 2022, and has until the new deadline to regain compliance by maintaining a closing bid price of $1.00 for 10 consecutive business days. While the extension does not affect the current trading of its stock on Nasdaq or its operations, failure to comply by the new deadline could result in delisting, though the company retains the right to appeal such a decision. Medicenna, focused on developing immunotherapies, is evaluating strategies to meet the compliance requirement.

Medicenna Therapeutics announced participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference, scheduled for April 25-26, 2023, in Toronto. Dr. Fahar Merchant, the President and CEO, will engage in a fireside chat on April 25 at 3:30 p.m. EDT. Investors can access the webcast here. Additionally, management will have one-on-one meetings at the event. Medicenna is focused on innovating immunotherapy treatments, including its IL-2 Superkine, MDNA11, designed to enhance cancer treatment by selectively targeting effector T cells and NK cells. The company’s bizaxofusp, an IL-4 Empowered Superkine, has been studied in clinical trials for recurrent GBM and holds FDA FastTrack and Orphan Drug status.

Medicenna Therapeutics Corp. (NASDAQ: MDNA) has unveiled promising preclinical data on novel IL-13 Superkines, specifically MDNA132 and MDNA213, at the 2023 AACR Annual Meeting. These Superkines target the IL-13Rα2 receptor, which is overexpressed in aggressive solid tumors. The data indicates that these Superkines selectively accumulate in the tumor microenvironment and can enhance the efficacy of immunotherapies.

Notably, applications like Anti-mCD3-MDNA132 and MDNA19-MDNA213 are designed to address immunologically “cold” tumors. The advancements presented signify a potential leap forward in precision immunotherapy.

Medicenna Therapeutics announced positive updates from its Phase 1/2 ABILITY study involving MDNA11, a next-generation IL-2 therapy. Notably, durable anti-cancer activity was observed in the first four dose escalation cohorts, including a fourth-line pancreatic cancer patient who achieved complete regression of a non-target lesion. Another patient with metastatic melanoma maintained stable disease for over 70 weeks. The latest data shows MDNA11 continues to stimulate anti-cancer immune cells effectively at higher doses. Upcoming data from the fifth and sixth cohorts are anticipated in Q2 and Q3 2023, respectively.

Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced on March 15, 2023, that an abstract has been accepted for a poster presentation at the AACR Annual Meeting in Orlando, Florida, from April 14-19, 2023.

The poster, titled Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine, will be presented on April 16, 2023, from 1:30 pm to 5:00 pm ET, highlighting preclinical studies of MDNA132 and BiSKITs™.

MDNA132 targets IL13Rα2, overexpressed in several cancer types, for directed immunotherapy delivery. The poster will be available post-event on Medicenna’s website.

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that Dr. Fahar Merchant, its President and CEO, will speak at the Oppenheimer 33rd Annual Healthcare Conference scheduled for March 14, 2023, at 2:40 PM ET. The event will take place virtually from March 13-15, 2023. Attendees can access the live webcast here. Medicenna is a clinical-stage immunotherapy company dedicated to developing innovative cancer treatments, including its lead product MDNA11 and the IL-4 Empowered Superkine, bizaxofusp, which has received FastTrack and Orphan Drug status.

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced a sales agreement with Oppenheimer & Co. to execute an "at-the-market" (ATM) offering of common shares valued up to $10 million. Medicenna will control the timing and amount of shares sold, with Oppenheimer facilitating sales at market prices. The offering will be conducted in the U.S., as the TSX has conditionally approved it. Proceeds from the offering will support general corporate purposes, including R&D and clinical trials. The registration statement for the sale has been filed but not yet effective, prohibiting any sales until it is.

Medicenna Therapeutics Corp. (NASDAQ: MDNA) reported positive advancements in its Phase 1/2 ABILITY study for MDNA11, now entering the sixth dose escalation cohort following promising safety and pharmacodynamic reviews. The study's fifth cohort demonstrated a significant increase in lymphocyte expansion without dose-limiting toxicities. Medicenna reported $36.2 million in cash as of December 31, 2022, expected to fund operations through Q2 2024. Additionally, preliminary pharmacokinetic and anti-tumor data from the fifth cohort are anticipated in Q1 2023, further bolstering the company's clinical development narrative.

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that Dr. Fahar Merchant, President and CEO, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference on February 9, 2023, at 3:55 PM ET. This conference will showcase their innovative immunotherapy developments, including the highly selective IL-2 Superkine, MDNA11, which targets cancer-killing cells. Medicenna is also advancing its IL-4 Empowered Superkine, MDNA55, which has received FDA Fast-Track and Orphan Drug designations. Interested parties can access the webcast via the provided link and find more details on Medicenna's website.